Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 57 articles:
HTML format
Text format



Single Articles


    November 2017
  1. PAN H, Gray R, Braybrooke J, Davies C, et al
    20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
    N Engl J Med. 2017;377:1836-1846.
    PubMed     Text format     Abstract available


  2. NAROD S, Booth CM, Foulkes WD
    Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792.
    PubMed     Text format    


  3. OIDE T, Mitsuishi T
    Pigmented Macule - A Skin Manifestation of Invasive Breast Cancer.
    N Engl J Med. 2017;377:1777.
    PubMed     Text format    



  4. Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
    N Engl J Med. 2017;377:1792-3.
    PubMed     Text format    


  5. GREENE AK, Voss SD, Maclellan RA
    Liposuction for Swelling in Patients with Lymphedema.
    N Engl J Med. 2017;377:1788-1789.
    PubMed     Text format    


    October 2017
  6. LEMERY S, Keegan P, Pazdur R
    First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
    N Engl J Med. 2017;377:1409-1412.
    PubMed     Text format    


    September 2017
  7. RAMASWAMI R, Morrow M, Jagsi R
    Contralateral Prophylactic Mastectomy.
    N Engl J Med. 2017;377:1288-1291.
    PubMed     Text format    


    August 2017
  8. RUADES NINFEA JI, Burdette-Radoux S, Wood ME
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:790-1.
    PubMed     Text format    


  9. SPURDLE AB, Goldgar DE, Easton DF
    More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795.
    PubMed     Text format    



  10. More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;377:795-6.
    PubMed     Text format    


  11. HIZAL M, Sendur MAN, Yalcin B
    Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791.
    PubMed     Text format    



  12. Adjuvant Capecitabine for Breast Cancer.
    N Engl J Med. 2017;377:791-2.
    PubMed     Text format    



  13. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Aug 9. doi: 10.1056/NEJMx170012.
    PubMed     Text format    


    July 2017
  14. HAYMART MR, Miller DC, Hawley ST
    Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
    N Engl J Med. 2017;377:203-206.
    PubMed     Text format    



  15. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jul 12. doi: 10.1056/NEJMx170011.
    PubMed     Text format    


    June 2017
  16. SCHWARTZ RS, Erban JK
    Timing of Metastasis in Breast Cancer.
    N Engl J Med. 2017;376:2486-2488.
    PubMed     Text format    


  17. LANNIN DR, Wang S
    Are Small Breast Cancers Good because They Are Small or Small because They Are Good?
    N Engl J Med. 2017;376:2286-91.
    PubMed     Text format    


  18. VON MINCKWITZ G, Procter M, de Azambuja E, Zardavas D, et al
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
    N Engl J Med. 2017 Jun 5. doi: 10.1056/NEJMoa1703643.
    PubMed     Text format     Abstract available


  19. ROBSON M, Im SA, Senkus E, Xu B, et al
    Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    N Engl J Med. 2017 Jun 4. doi: 10.1056/NEJMoa1706450.
    PubMed     Text format     Abstract available


  20. MASUDA N, Lee SJ, Ohtani S, Im YH, et al
    Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    N Engl J Med. 2017;376:2147-2159.
    PubMed     Text format     Abstract available


    May 2017
  21. MOVASSAGH M, Mudvari P, Horvath A
    Co-Occurrence of COMT and BRCA1/2 Variants in a Population.
    N Engl J Med. 2017;376:2090-2091.
    PubMed     Text format    


    January 2017
  22. PLICHTA JK, Hughes K
    Radiation-Induced Angiosarcoma after Breast-Cancer Treatment.
    N Engl J Med. 2017;376:367.
    PubMed     Text format    


  23. DE GRAMONT A, Herrera A, de Gramont A
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    PubMed     Text format    


  24. ARAKI K, Miyoshi Y
    Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:288.
    PubMed     Text format    



  25. Ribociclib for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2017;376:289.
    PubMed     Text format    


  26. BRENTNALL AR, Duffy SW, Cuzick J
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:94.
    PubMed     Text format    



  27. Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-95.
    PubMed     Text format    


  28. KOPANS DB
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93-4.
    PubMed     Text format    


  29. JATOI I, Anderson WF
    Breast-Cancer Tumor Size and Screening Effectiveness.
    N Engl J Med. 2017;376:93.
    PubMed     Text format    


    December 2016
  30. LYCETTE J
    Neglected - Cancer Care and Mental Health in Rural America.
    N Engl J Med. 2016;375:2220-2221.
    PubMed     Text format    


  31. BLOK EJ, van de Velde CJ, Smit VT
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199.
    PubMed     Text format    



  32. 70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2201.
    PubMed     Text format    


  33. THEWES B, Prins J, Friedlander M
    70-Gene Signature in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:2199-2200.
    PubMed     Text format    


    November 2016
  34. FINN RS, Martin M, Rugo HS, Jones S, et al
    Palbociclib and Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2016;375:1925-1936.
    PubMed     Text format     Abstract available


  35. SHERR CJ
    A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.
    N Engl J Med. 2016;375:1920-1923.
    PubMed     Text format    


  36. WOLFF AC
    CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard.
    N Engl J Med. 2016;375:1993-1994.
    PubMed     Text format    


    October 2016
  37. BUYSE M, Saad ED, Burzykowski T
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    PubMed     Text format    



  38. Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1591-1594.
    PubMed     Text format    


  39. SANZ A, Del Valle ML
    Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    PubMed     Text format    



  40. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
    N Engl J Med. 2016;375:1590-1591.
    PubMed     Text format    


  41. HARRINGTON D, Parmigiani G
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1593-4.
    PubMed     Text format    


  42. JOENSUU H
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:1592.
    PubMed     Text format    


  43. WELCH HG, Prorok PC, O'Malley AJ, Kramer BS, et al
    Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.
    N Engl J Med. 2016;375:1438-1447.
    PubMed     Text format     Abstract available


  44. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


    August 2016
  45. HUDIS CA, Dickler M
    Increasing Precision in Adjuvant Therapy for Breast Cancer.
    N Engl J Med. 2016;375:790-1.
    PubMed     Text format    


  46. CARDOSO F, van't Veer LJ, Bogaerts J, Slaets L, et al
    70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    N Engl J Med. 2016;375:717-29.
    PubMed     Text format     Abstract available


  47. HUNTER DJ
    Uncertainty in the Era of Precision Medicine.
    N Engl J Med. 2016;375:711-3.
    PubMed     Text format    


    July 2016
  48. POLLARD JW
    Defining Metastatic Cell Latency.
    N Engl J Med. 2016;375:280-2.
    PubMed     Text format    


  49. GOSS PE, Ingle JN, Pritchard KI, Robert NJ, et al
    Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
    N Engl J Med. 2016;375:209-19.
    PubMed     Text format     Abstract available


  50. CAREY LA, Winer EP
    I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.
    N Engl J Med. 2016;375:83-4.
    PubMed     Text format    


  51. RUGO HS, Olopade OI, DeMichele A, Yau C, et al
    Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    N Engl J Med. 2016;375:23-34.
    PubMed     Text format     Abstract available


  52. PARK JW, Liu MC, Yee D, Yau C, et al
    Adaptive Randomization of Neratinib in Early Breast Cancer.
    N Engl J Med. 2016;375:11-22.
    PubMed     Text format     Abstract available


    June 2016
  53. MACINNIS RJ, Pike MC, Hopper JL
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403-4.
    PubMed     Text format    


  54. KARAM A
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2403.
    PubMed     Text format    


  55. HARTMANN LC, Lindor NM
    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    N Engl J Med. 2016;374:2404.
    PubMed     Text format    


  56. MENDELL JT
    Targeting a Long Noncoding RNA in Breast Cancer.
    N Engl J Med. 2016;374:2287-9.
    PubMed     Text format    


  57. CHLEBOWSKI RT, Budoff MJ
    Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: